aiCRISPRL: An Artificial Intelligence Platform for Stem Cell and Organoid Simulation with Extensive Gene Editing Capabilities

Abstract

CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease 9) provides powerful gene-editing tools that are applicable for gene therapy of a variety of diseases including, but not limited to cancer, rare diseases, and heart disease. In the current study, we first re-examined our artificial stem cell and organoid simulations that were generated by our literature validated DeepNEU AI platform from the perspective of gene-editing. We then evaluated the aiCRISPRL (aiCRISPR-Like) application of the DeepNEU platform by directly comparing the CRISPR-Cas9 gene-editing approach with the DeepNEU derived aiCRISPRL capabilities using artificial simulated HeLa cells (aiHeLa). To accomplish this, we evaluated the aiCRISPRL like capabilities of DeepNEU to introduce a series of specific mutations into the MutS homolog 2 (MSH2) gene to assess DNA Mismatch Repair (MMR). This approach permits a comparative assessment of CRISPR-Cas9 and aiCRISPRL technologies following the introduction of specific MSH2 mutations. When combined with our previous body of gene editing research, the current data indicates that aiCRISPRL is an advanced AI platform technology that can be used for rapid prototyping and multiple scenario simulation in genomic research to complement wet-lab based gene-editing technologies.